BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25662406)

  • 1. Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression.
    Noguchi M; Arai G; Matsumoto K; Naito S; Moriya F; Suekane S; Komatsu N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2015 Apr; 64(4):493-505. PubMed ID: 25662406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.
    Noguchi M; Arai G; Egawa S; Ohyama C; Naito S; Matsumoto K; Uemura H; Nakagawa M; Nasu Y; Eto M; Suekane S; Sasada T; Shichijo S; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2020 May; 69(5):847-857. PubMed ID: 32025848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele.
    Sakamoto S; Matsueda S; Takamori S; Toh U; Noguchi M; Yutani S; Yamada A; Shichijo S; Yamada T; Suekane S; Kawano K; Sasada T; Hattori N; Kohno N; Itoh K
    Cancer Sci; 2015 Oct; 106(10):1257-63. PubMed ID: 26212219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients.
    Takahashi R; Ishibashi Y; Hiraoka K; Matsueda S; Kawano K; Kawahara A; Kage M; Ohshima K; Yamanaka R; Shichijo S; Shirouzu K; Itoh K; Sasada T
    Cancer Sci; 2013 Oct; 104(10):1285-94. PubMed ID: 23829867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients.
    Takedatsu H; Shichijo S; Katagiri K; Sawamizu H; Sata M; Itoh K
    Clin Cancer Res; 2004 Feb; 10(3):1112-20. PubMed ID: 14871991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.
    Matsueda S; Takedatsu H; Yao A; Tanaka M; Noguchi M; Itoh K; Harada M
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6933-43. PubMed ID: 16203785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
    Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients.
    Iwasa S; Yamada Y; Heike Y; Shoji H; Honma Y; Komatsu N; Matsueda S; Yamada A; Morita M; Yamaguchi R; Tanaka N; Kawahara A; Kage M; Shichijo S; Sasada T; Itoh K
    Cancer Sci; 2016 May; 107(5):590-600. PubMed ID: 26920496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer.
    Obara W; Sato F; Takeda K; Kato R; Kato Y; Kanehira M; Takata R; Mimata H; Sugai T; Nakamura Y; Fujioka T
    Cancer Sci; 2017 Jul; 108(7):1452-1457. PubMed ID: 28498618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles.
    Terasaki Y; Shichijo S; Niu Y; Komatsu N; Noguchi M; Todo S; Itoh K
    Cancer Immunol Immunother; 2009 Nov; 58(11):1877-85. PubMed ID: 19330328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
    Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
    J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles.
    Mohamed ER; Naito M; Terasaki Y; Niu Y; Gohara S; Komatsu N; Shichijo S; Itoh K; Noguchi M
    Int J Oncol; 2009 Feb; 34(2):529-36. PubMed ID: 19148489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles.
    Naito M; Komohara Y; Ishihara Y; Noguchi M; Yamashita Y; Shirakusa T; Yamada A; Itoh K; Harada M
    Br J Cancer; 2007 Dec; 97(12):1648-54. PubMed ID: 18043580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
    Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles.
    Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco MA; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
    Int Immunopharmacol; 2015 May; 26(1):133-8. PubMed ID: 25819666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.
    Minami T; Matsueda S; Takedatsu H; Tanaka M; Noguchi M; Uemura H; Itoh K; Harada M
    Cancer Immunol Immunother; 2007 May; 56(5):689-98. PubMed ID: 16937115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients.
    Mine T; Gouhara R; Hida N; Imai N; Azuma K; Rikimaru T; Katagiri K; Nishikori M; Sukehiro A; Nakagawa M; Yamada A; Aizawa H; Shirouzu K; Itoh K; Yamana H
    Cancer Sci; 2003 Jun; 94(6):548-56. PubMed ID: 12824881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11
    Sakamoto S; Matsueda S; Takamori S; Toh U; Noguchi M; Yutani S; Yamada A; Shichijo S; Yamada T; Suekane S; Kawano K; Naitou M; Sasada T; Hattori N; Kohno N; Itoh K
    Cancer Sci; 2017 Apr; 108(4):598-603. PubMed ID: 28178396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
    Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
    Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.